Randomized clinical trial of adenosine 5′-triphosphate on tumor growth and survival in advanced lung cancer patients

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Anti-Cancer Drugs

• Publication date

  2003-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00001813-200309000-00009PMID 14501386
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial.

  2002cited by this paper
• Pharmacokinetics of intravenous ATP in cancer patients

  2000cited by this paper
• Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer.

  2000cited by this paper
• Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and Stage IV non-small cell lung cancer

  1998cited by this paper
• Glutathione and the rate of cellular proliferation determine tumour cell sensitivity to tumour necrosis factor in vivo.

  1997cited by this paper
• Purines and cell death

  1996cited by this paper
• The Cytolytic P2Z Receptor for Extracellular ATP Identified as a P2X Receptor (P2X7)

  1996cited by this paper
• ROLE OF ADENOSINE 5' TRIPHOSPHATASE IN LYMPHOKINE ACTIVATED (LAK) KILLING OF HUMAN TUMOR CELLS

  1995cited by this paper
• Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays

  1995cited by this paper
• Effect of intraperitoneal ATP on tumor growth and bone marrow radiation tolerance.

  1995cited by this paper
• Inhibition of cancer growth and selective glutathione depletion in Ehrlich tumour cells in vivo by extracellular ATP.

  1994cited by this paper
• Growth inhibition of breast cancer cells induced by exogenous ATP

  1993cited by this paper
• P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells.

  1992cited by this paper
• Tumor stage in non-small cell carcinoma of the lung.

  1991cited by this paper
• Extracellular ATP as a trigger for apoptosis or programmed cell death

  1991cited by this paper
• Investigation on phosphate dependent glutaminase (EC 3.5.1.2) activity in host tissues of EAC-bearing mice and response of liver EC 3.5.1.2 on Cu-ATP therapy.

  1991cited by this paper
• Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation.

  1990cited by this paper
• Antitumour activities of copper-ATP complex on transplantable murine lymphoma.

  1990cited by this paper
• Experimental cancer therapy in mice by adenine nucleotides.

  1988cited by this paper
• External ATP-induced passive permeability change and cell lysis of cultured transformed cells: action in serum-containing growth media.

  1988cited by this paper
• Growth inhibition of transformed mouse fibroblasts by adenine nucleotides occurs via generation of extracellular adenosine.

  1988cited by this paper
• Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle

  1983cited by this paper
• Effect of nutritional status on responses to therapy.

  1982cited by this paper
• Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

  1980cited by this paper
• Prognostic factors for survival in patients with inoperable lung cancer.

  1980cited by this paper
• The clinical evaluation of chemotherapeutic agents in cancer

  1949cited by this paper
• Evaluation of Chemotherapeutic Agents

  1949cited by this paper

• Role and Therapeutic Potential of P2X7 Receptor in Lung Cancer Progression.

  2024cites this paper
• Purinergic P2Y2 and P2X4 Receptors Are Involved in the Epithelial-Mesenchymal Transition and Metastatic Potential of Gastric Cancer Derived Cell Lines

  2021cites this paper
• Autocrine and paracrine purinergic signaling in the most lethal types of cancer

  2021cites this paper
• A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy

  2021cites this paper
• P2Y Receptors for Extracellular Nucleotides: Contributions to Cancer Progression and Therapeutic Implications.

  2021cites this paper
• Role of coenzymes in cancer metabolism.

  2020cites this paper
• Small-molecule P2RX7 activator sensitizes tumor to immunotherapy and vaccinates mouse against tumor re-challenge

  2020cites this paper
• Osteocytes and Bone Metastasis

  2020cites this paper
• The P2X7 purinergic receptor: a potential therapeutic target for lung cancer

  2020cites this paper
• Management of Cancer Cachexia: ASCO Guideline.

  2020cites this paper
• Targeting the Tumor Microenvironment for a More Effective and Efficient Cancer Immunotherapy

  2020cites this paper
• Drug transporters in the development of multidrug resistance in colorectal cancer

  2020cites this paper
• The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

  2018cites this paper
• Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells.

  2017cites this paper
• Purinergic Signalling: Therapeutic Developments

  2017cites this paper
• Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives

  2017cites this paper
• P2Y2 Receptor Functions in Cancer: A Perspective in the Context of Colorectal Cancer.

  2017cites this paper
• P2X7 Receptor as a Therapeutic Target.

  2016cites this paper
• Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells

  2016influential citation
• Papel do receptor P2X7 e da enzima CD39/NTPDASE1 na resposta à radioterapia em gliomas

  2016cites this paper
• Systematic analysis of design and stratification for phase III trials in first‐line advanced non‐small cell lung cancer

  2015cites this paper
• Role of ion channels in regulating Ca2+ homeostasis during the interplay between immune and cancer cells

  2015cites this paper
• Expression and function of P2 receptors in hematopoietic stem and progenitor cells.

  2015cites this paper
• The effect of thalidomide on cachexia in upper gastrointestinal cancer

  2015cites this paper
• Multidrug Resistance-Associated Protein 2 Expression Is Upregulated by Adenosine 5’-Triphosphate in Colorectal Cancer Cells and Enhances Their Survival to Chemotherapeutic Drugs

  2015cites this paper
• Effects of adenine nucleotide agents and their therapeutic potential on triple negative breast cancer

  2014influential citation
• Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis

  2014cites this paper
• P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer

  2013cites this paper
• Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice.

  2012cites this paper
• P2X7 receptors and epithelial cancers

  2012cites this paper
• The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART

  2011cites this paper
• Kinetics and effects of orally administered ATP

  2011cites this paper
• Extracellular ATP enhances in vitro invasion of prostate cancer cells by activating Rho GTPase and upregulating MMPs expression.

  2010cites this paper
• Randomized clinical trial on the effects of adenosine 5'-triphosphate infusions on quality of life, functional status, and fatigue in preterminal cancer patients.

  2010cites this paper
• P2X7-mediated chemoprevention of epithelial cancers

  2009cites this paper
• Effect of adenosine 5′-triphosphate infusions on the nutritional status and survival of preterminal cancer patients

  2009cites this paper
• Management of erectile function by penile purinergic p2 receptors in the diabetic rat.

  2009cites this paper
• Purinergic receptor‐mediated effects of adenosine 5′‐triphosphate in urological malignant diseases

  2009cites this paper
• Effect of extracellular ATP on the growth of hormone‐refractory prostate cancer in vivo

  2008cites this paper
• Exogenous Adenosine 5′-triphosphate does not Improve Survival in Rats with Acute Liver Failure

  2008influential citation
• Die Wirkung von 5'Adenosintriphosphat (ATP) auf humane plasmazytoide dendritische Zellen

  2008cites this paper
• Extracellular ATP and Cancer—An Overview with Special Reference to P2 Purinergic Receptors

  2008cites this paper
• Treatment adherence and patients’ acceptance of home infusions with adenosine 5′-triphosphate (ATP) in palliative home care

  2008cites this paper
• Cell Death Induced by Uridine 5'-triphosphate (UTP) in Contrast to Adenosine 5'-triphosphate (ATP) in Human Epidermoid Carcinoma Cells (A-431)

  2008cites this paper
• Role of extracellular ATP in immunity and intestinal defence: effects on intestinal permeability and enterocyte-driven inflammatory response

  2007cites this paper
• Purinergic receptor‐mediated effects of ATP in high‐grade bladder cancer

  2007cites this paper
• ATP as a modulator of inflammation and oxidative stress

  2007cites this paper
• Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients

  2007cites this paper
• Invited Lectures

  2006cites this paper
• Treatment of Cachexia in the Elderly

  2006cites this paper
• Gateways to clinical trials.

  2006cites this paper
• P2 receptors and cancer.

  2006cites this paper
• Pharmaco-Nutritional Supports for the Treatment of Cancer Cachexia

  2006cites this paper
• Lung cancer.

  2005cites this paper
• Immunoregulatory effects of adenosine 5′‐triphosphate on cytokine release from stimulated whole blood

  2005cites this paper